These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

270 related articles for article (PubMed ID: 32066817)

  • 1. The kinase polypharmacology landscape of clinical PARP inhibitors.
    Antolin AA; Ameratunga M; Banerji U; Clarke PA; Workman P; Al-Lazikani B
    Sci Rep; 2020 Feb; 10(1):2585. PubMed ID: 32066817
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Concepts and Molecular Aspects in the Polypharmacology of PARP-1 Inhibitors.
    Passeri D; Camaioni E; Liscio P; Sabbatini P; Ferri M; Carotti A; Giacchè N; Pellicciari R; Gioiello A; Macchiarulo A
    ChemMedChem; 2016 Jun; 11(12):1219-26. PubMed ID: 26424664
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Real world experience of poly (ADP-ribose) polymerase inhibitor use in a community oncology practice.
    Eakin CM; Ewongwo A; Pendleton L; Monk BJ; Chase DM
    Gynecol Oncol; 2020 Oct; 159(1):112-117. PubMed ID: 32811682
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Movement of Poly-ADP Ribose (PARP) Inhibition into Frontline Treatment of Ovarian Cancer.
    Onstad M; Coleman RL; Westin SN
    Drugs; 2020 Oct; 80(15):1525-1535. PubMed ID: 32852746
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative safety and tolerability of approved PARP inhibitors in cancer: A systematic review and network meta-analysis.
    Cai Z; Liu C; Chang C; Shen C; Yin Y; Yin X; Jiang Z; Zhao Z; Mu M; Cao D; Zhang L; Zhang B
    Pharmacol Res; 2021 Oct; 172():105808. PubMed ID: 34389457
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Structural Basis for Potency and Promiscuity in Poly(ADP-ribose) Polymerase (PARP) and Tankyrase Inhibitors.
    Thorsell AG; Ekblad T; Karlberg T; Löw M; Pinto AF; Trésaugues L; Moche M; Cohen MS; Schüler H
    J Med Chem; 2017 Feb; 60(4):1262-1271. PubMed ID: 28001384
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PARP inhibitors for ovarian cancer.
    Med Lett Drugs Ther; 2017 Dec; 59(1535):200-202. PubMed ID: 29186085
    [No Abstract]   [Full Text] [Related]  

  • 8. Cost-effectiveness of niraparib, rucaparib, and olaparib for treatment of platinum-resistant, recurrent ovarian carcinoma.
    Wolford JE; Bai J; Moore KN; Kristeleit R; Monk BJ; Tewari KS
    Gynecol Oncol; 2020 May; 157(2):500-507. PubMed ID: 32173049
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of different side effects between PARP inhibitors and their polypharmacological multi-target rationale.
    Sandhu D; Antolin AA; Cox AR; Jones AM
    Br J Clin Pharmacol; 2022 Feb; 88(2):742-752. PubMed ID: 34327724
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PARP inhibitors in ovarian cancer: Sensitivity prediction and resistance mechanisms.
    Jiang X; Li X; Li W; Bai H; Zhang Z
    J Cell Mol Med; 2019 Apr; 23(4):2303-2313. PubMed ID: 30672100
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PARP inhibitors: polypharmacology versus selective inhibition.
    Ekblad T; Camaioni E; Schüler H; Macchiarulo A
    FEBS J; 2013 Aug; 280(15):3563-75. PubMed ID: 23601167
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Real-world evidence of poly ADP-ribose polymerase inhibitors in the treatment of ovarian cancer: A systematic literature review.
    Borrelli EP; McGladrigan CG
    J Oncol Pharm Pract; 2020 Dec; 26(8):1977-1986. PubMed ID: 32659172
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differential Potential of Pharmacological PARP Inhibitors for Inhibiting Cell Proliferation and Inducing Apoptosis in Human Breast Cancer Cells.
    Węsierska-Gądek J; Mauritz M; Mitulovic G; Cupo M
    J Cell Biochem; 2015 Dec; 116(12):2824-39. PubMed ID: 25981734
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The non-canonical target PARP16 contributes to polypharmacology of the PARP inhibitor talazoparib and its synergy with WEE1 inhibitors.
    Palve V; Knezevic CE; Bejan DS; Luo Y; Li X; Novakova S; Welsh EA; Fang B; Kinose F; Haura EB; Monteiro AN; Koomen JM; Cohen MS; Lawrence HR; Rix U
    Cell Chem Biol; 2022 Feb; 29(2):202-214.e7. PubMed ID: 34329582
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Linking off-target kinase pharmacology to the differential cellular effects observed among PARP inhibitors.
    Antolín AA; Mestres J
    Oncotarget; 2014 May; 5(10):3023-8. PubMed ID: 24632590
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Investigation of the Complexes Formed between PARP1 Inhibitors and PARP1 G-Quadruplex at the Gene Promoter Region.
    Dallavalle S; Princiotto S; Mattio LM; Artali R; Musso L; Aviñó A; Eritja R; Pisano C; Gargallo R; Mazzini S
    Int J Mol Sci; 2021 Aug; 22(16):. PubMed ID: 34445442
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PARP Inhibitors in Prostate Cancer.
    Grewal K; Grewal K; Tabbara IA
    Anticancer Res; 2021 Feb; 41(2):551-556. PubMed ID: 33517260
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Cancer therapy by PARP inhibitors].
    Seimiya H
    Nihon Rinsho; 2015 Aug; 73(8):1330-5. PubMed ID: 26281686
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The poly (ADP ribose) polymerase inhibitor niraparib: Management of toxicities.
    Moore KN; Mirza MR; Matulonis UA
    Gynecol Oncol; 2018 Apr; 149(1):214-220. PubMed ID: 29397193
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Free energy calculation provides insight into the action mechanism of selective PARP-1 inhibitor.
    Cao R
    J Mol Model; 2016 Apr; 22(4):74. PubMed ID: 26969680
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.